Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences Fund (JFNCX)

52.96
+0.70
+(1.34%)
At close: 8:01:22 PM EDT

Top 10 Holdings (41.48% of Total Assets)

SymbolCompany% Assets
Eli Lilly and Company 10.12%
UnitedHealth Group Incorporated 5.99%
AstraZeneca PLC 4.00%
Novo Nordisk A/S 3.40%
Johnson & Johnson 3.31%
Abbott Laboratories 3.18%
Boston Scientific Corporation 3.09%
Sanofi 2.89%
Amgen Inc. 2.77%
AbbVie Inc. 2.75%

Sector Weightings

SectorJFNCX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 0.02%
Stocks 99.18%
Bonds 0.00%
Others 0.55%
Preferred 0.22%
Convertible 0.04%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average JFNCX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.2 5.28
Price/Sales 0.44 2.06
Price/Cashflow 0.05 17.54
Median Market Cap 74,385.25 34,862.81
3 Year Earnings Growth 8.88 32.48

Bond Holdings

Performance & Risk

YTD Return -7.27%
5y Average Return 5.39%
Rank in Category (ytd) 33
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.68
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 4.66B
YTD Return 0.39%
Yield 0.00%
Morningstar Rating
Inception Date Jul 06, 2009

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers